Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
South Korea
National Cancer Center, Goyang-si, Gyeonggi-do Korea University Anam Hospital, Seoul Hanyang University Seoul Hospital, Seoul Severance Hospital, Yonsei University Health System, Seoul